• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Driving innovation from discovery to access: Meeting report of the 7 Global Forum on TB Vaccines (8-10 October 2024, Rio de Janeiro, Brazil).推动从发现到可及的创新:第七届全球结核病疫苗论坛会议报告(2024年10月8 - 10日,巴西里约热内卢)
Gates Open Res. 2025 Aug 27;9:65. doi: 10.12688/gatesopenres.16360.1. eCollection 2025.
2
Tuberculosis Prevention, Control, and Elimination结核病的预防、控制与消除
3
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.快速分子检测结核分枝杆菌和结核分枝杆菌耐药性:受检者和提供者观点的定性证据综合评价。
Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD014877. doi: 10.1002/14651858.CD014877.pub2.
4
Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development.病毒载体结核病疫苗的研究进展及结核病疫苗研发的最新发现。
Front Immunol. 2022 Jun 23;13:895020. doi: 10.3389/fimmu.2022.895020. eCollection 2022.
5
Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review.梳理关于新型和重新利用的结核病疫苗实施的现有知识体系:一项范围综述。
PLOS Glob Public Health. 2024 Aug 22;4(8):e0002885. doi: 10.1371/journal.pgph.0002885. eCollection 2024.
6
What are the key features of an equitable global vaccine strategy for the next pandemic? A qualitative study of pandemic control experts.下一次大流行的公平全球疫苗战略的关键特征是什么?一项针对大流行控制专家的定性研究。
Vaccine. 2025 Aug 13;61:127377. doi: 10.1016/j.vaccine.2025.127377. Epub 2025 Jun 11.
7
Meeting summary: Global vaccine and immunization research forum, 2023.会议总结:2023年全球疫苗与免疫研究论坛
Vaccine. 2025 Feb 6;46:126686. doi: 10.1016/j.vaccine.2024.126686. Epub 2025 Jan 5.
8
Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.1980年至2023年全球、区域和国家儿童常规疫苗接种覆盖率趋势及2030年预测:2023年全球疾病负担研究的系统分析
Lancet. 2025 Jun 24. doi: 10.1016/S0140-6736(25)01037-2.
9
Drivers of human papillomavirus vaccine uptake in migrant populations and interventions to improve coverage: a systematic review and meta-analysis.移民人群中人类乳头瘤病毒疫苗接种的驱动因素及提高覆盖率的干预措施:一项系统评价和荟萃分析
Lancet Public Health. 2025 Aug;10(8):e693-e711. doi: 10.1016/S2468-2667(25)00148-3.
10
Expanding vaccination access in underserved communities across Maryland through a collaborative approach.通过合作方式扩大马里兰州服务不足社区的疫苗接种机会。
J Am Pharm Assoc (2003). 2025 Jul-Aug;65(4):102389. doi: 10.1016/j.japh.2025.102389. Epub 2025 Mar 21.

本文引用的文献

1
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial.疫苗H56:IC31在降低成功治疗药物敏感型肺结核的HIV阴性成人结核病复发率方面的免疫原性、安全性和疗效:一项双盲、随机、安慰剂对照的2b期试验。
Lancet Infect Dis. 2025 Jul;25(7):751-763. doi: 10.1016/S1473-3099(24)00814-4. Epub 2025 Mar 5.
2
Prevention of tuberculosis in cynomolgus macaques by an attenuated Mycobacterium tuberculosis vaccine candidate.一种减毒结核分枝杆菌候选疫苗对食蟹猴结核病的预防作用
Nat Commun. 2025 Feb 25;16(1):1957. doi: 10.1038/s41467-025-57090-4.
3
Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes.静脉注射卡介苗介导的抗结核保护作用需要CD4 + T细胞和CD8α +淋巴细胞。
J Exp Med. 2025 Apr 7;222(4). doi: 10.1084/jem.20241571. Epub 2025 Feb 6.
4
Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.新型含佐剂结核疫苗候选蛋白诱导强烈免疫反应及有效保护。
Sci Rep. 2025 Jan 13;15(1):1886. doi: 10.1038/s41598-024-84667-8.
5
Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data.卡介苗初种疫苗预防结核分枝杆菌感染和结核病风险的有效性:个体参与者数据的荟萃分析
Lancet Microbe. 2025 Feb;6(2):100961. doi: 10.1016/j.lanmic.2024.100961. Epub 2024 Dec 19.
6
A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults.一项评估先前接种过卡介苗的健康英国成年人气溶胶卡介苗感染安全性的剂量递增研究。
Front Immunol. 2024 Nov 14;15:1427371. doi: 10.3389/fimmu.2024.1427371. eCollection 2024.
7
Indoleamine-2,3-dioxygenase inhibition improves immunity and is safe for concurrent use with cART during Mtb/SIV coinfection.吲哚胺-2,3-双加氧酶抑制可增强免疫力,在结核分枝杆菌/猴免疫缺陷病毒合并感染期间与抗逆转录病毒治疗同时使用是安全的。
JCI Insight. 2024 Jul 2;9(15):e179317. doi: 10.1172/jci.insight.179317.
8
Implications of subclinical tuberculosis for vaccine trial design and global effect.亚临床结核病对疫苗试验设计和全球影响的意义。
Lancet Microbe. 2024 Oct;5(10):100895. doi: 10.1016/S2666-5247(24)00127-7. Epub 2024 Jul 1.
9
Mycobacterium tuberculosis strain with deletions in menT3 and menT4 is attenuated and confers protection in mice and guinea pigs.结核分枝杆菌 menT3 和 menT4 缺失株的减毒特性及其在小鼠和豚鼠中的保护作用。
Nat Commun. 2024 Jun 27;15(1):5467. doi: 10.1038/s41467-024-49246-5.
10
Review of Current Tuberculosis Human Infection Studies for Use in Accelerating Tuberculosis Vaccine Development: A Meeting Report.当前用于加速结核病疫苗开发的结核病人体感染研究综述:会议报告。
J Infect Dis. 2024 Aug 16;230(2):e457-e464. doi: 10.1093/infdis/jiae238.

推动从发现到可及的创新:第七届全球结核病疫苗论坛会议报告(2024年10月8 - 10日,巴西里约热内卢)

Driving innovation from discovery to access: Meeting report of the 7 Global Forum on TB Vaccines (8-10 October 2024, Rio de Janeiro, Brazil).

作者信息

Palmer Shaun, Clark Rebecca A, Connell Bridgette J, Muwanga Vanessa Mwebaza, Coelho Arthur, Ogongo Paul, Young Carly

机构信息

Stichting International Aids Vaccine Initiative, Amsterdam, 1013 NH, The Netherlands.

Stop TB Partnership Working Group on New Vaccines, New York, NY 10004, USA.

出版信息

Gates Open Res. 2025 Aug 27;9:65. doi: 10.12688/gatesopenres.16360.1. eCollection 2025.

DOI:10.12688/gatesopenres.16360.1
PMID:40896556
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12391588/
Abstract

We urgently need novel, effective, and accessible vaccines to end tuberculosis (TB) as a public health crisis. The 7th Global Forum on TB Vaccines was convened from 8-10 October 2024 in Rio de Janeiro, Brazil. Under the theme of "Driving innovation from discovery to access," the program covered the breadth of TB vaccine research and development (R&D) through implementation, while underscoring the need for greater innovation and investments to advance development and ensure rapid, affordable, and equitable access. Participants shared the latest research on: approaches to diversify the TB vaccine pipeline, candidates advancing through late-stage trials toward licensure, and efforts to ensure new TB vaccines reach the populations that most need them. The forum provided a platform to learn from diverse experts across the field, including researchers, industry, funders, civil society, and affected communities. Participants examined cross-cutting enablers throughout, including opportunities to establish novel partnership and financing models, enhance open science, optimize R&D practices, and strengthen leadership and engagement with community members and high burden countries alike. In this report, we synthesize key themes and findings from the meeting, highlighting progress and priorities in the TB vaccine field.

摘要

我们迫切需要新颖、有效且可及的疫苗,以终结作为公共卫生危机的结核病。第七届全球结核病疫苗论坛于2024年10月8日至10日在巴西里约热内卢召开。会议主题为“推动从发现到可及的创新”,议程涵盖了结核病疫苗研发从实施到应用的各个方面,同时强调需要加大创新和投资力度,以推动研发进程,并确保快速、可负担且公平的可及性。与会者分享了以下方面的最新研究:使结核病疫苗研发产品线多样化的方法、正通过后期试验迈向获批的候选疫苗,以及确保新型结核病疫苗惠及最有需求人群的努力。该论坛提供了一个平台,让来自该领域不同专家,包括研究人员、产业界、资助者、民间社会和受影响社区的人士能够相互学习。与会者自始至终审视了贯穿各领域的推动因素,包括建立新型伙伴关系和融资模式、加强开放科学、优化研发实践,以及加强与社区成员和高负担国家的领导力及互动的机会。在本报告中,我们综合了会议的关键主题和研究结果,突出了结核病疫苗领域的进展和优先事项。